fx-1

FX1 is an effective and selective BCL6 inhibitor (IC50: 35 μM).

FX-11 (LDHA Inhibitor FX11) is A potent, selective and competitive specific inhibitor of lactate dehydrogenase A (LDHA) with a Ki of 8 μM. FX-11 can activate PKM2 (pyruvate kinase M2). FX-11 can reduce ATP levels, induce oxidative stress and ROS production, and cause cell death. FX-11 appeared antitumor activity during xenotransplantation of lymphoma and pancreatic cancer.

FX-171-C is a non-competitive deubiquitinase inhibitor with an IC50 of 1.4 µM.

Tafamidis (Fx-1006A) is a kinetic stabilizer of transthyretin (TTR) that prevents amyloidogenesis by wild-type and mutant TTRs. It binds to TTR with negative cooperativity (Kd1: 3 nM; Kd2: 278 nM) to stabilize the TTR dimer-dimer interface and inhibit tetrameric dissociation. Tafamidis stabilizes wild-type and clinically significant V30M and V122I mutant TTR amyloidogenic homotetramers (EC50s: 2.7-3.2 μM) under fibril-promoting, denaturing, and physiological conditions in vitro. It stabilizes TTR heterotetramers containing wild-type and mutant subunits ex vivo in human plasma derived from patients carrying V30M or V1221 mutations when used at a concentration of 7.2 μM. Formulations containing tafamidis have been used for the treatment of familial amyloid polyneuropathy.

Tafamidis meglumine (Fx-1006A) is a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.

Nedometinib (NFX-179) is a selective mitogen-activated protein kinase kinase (MEK1) inhibitor with anticancer and antitumor activity, inhibits MAPK pathway signaling in the skin, inhibits the growth of human squamous cell lines in a dose-dependent manner, and can be used to study malignant tumors.

FX12 acts as a selective inhibitor and degrader of the RNF5 E3 ubiquitin ligase. It directly binds to RNF5, inhibiting its E3 activity in vitro and facilitates the proteasomal degradation of RNF5 in cells through ERAD.

cMCoFx1 is an effective and selective FXIIa cyclic peptide inhibitor. It exhibits high binding affinity for FXIIa (KD: 900 pM) and potent inhibitory activity (Ki: 370 pM). cMCoFx1 effectively suppresses the intrinsic coagulation pathway, demonstrates high stability in serum, and shows no cytotoxicity.

FX-909 is a covalent peroxisome proliferator-activated receptor gamma ( PPARG ) inverse agonist. FX-909 can be used for the research of cancer .

FX-06 (Fibrin-derived peptide Bβ15-42) is derived from the fibrin Bbeta chain and interacts with VE-cadherin to inhibit leukocyte transmigration while initiating VE-cadherin-mediated signaling pathways. This compound is utilized in researching ischemia/reperfusion injury and Dengue shock syndrome (DSS) [1] [2] [4].